Screener
G&A at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: Summit Therapeutics’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 5:00 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001599298-26-000039
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development (1) | $132,618 | $51,265 |
| General and administrative | 62,594 | 15,586 |
| Total operating expenses | 195,212 | 66,851 |
| Other income, net | 5,788 | 3,938 |
| Net loss | $(189,424) | $(62,913) |
| Net loss per share: | ||
| Basic and diluted | $(0.24) | $(0.09) |
Item 1. Financial Statements.
FAQ
- What is Summit Therapeutics's G&A?
- Summit Therapeutics (SMMT) reported G&A of $62.59M in Q1 2026.
- How has Summit Therapeutics's G&A changed year-over-year?
- Summit Therapeutics's G&A increased by 301.6% year-over-year, from $15.59M to $62.59M.
- What is the long-term trend for Summit Therapeutics's G&A?
- Over 4 years (2021 to 2025), Summit Therapeutics's G&A has grown at a 120.4% compound annual growth rate (CAGR), from $23.61M to $556.75M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about Summit Therapeutics's g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude